These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 19528470)

  • 41. TMED10 Protein Interferes with Transforming Growth Factor (TGF)-β Signaling by Disrupting TGF-β Receptor Complex Formation.
    Nakano N; Tsuchiya Y; Kako K; Umezaki K; Sano K; Ikeno S; Otsuka E; Shigeta M; Nakagawa A; Sakata N; Itoh F; Nakano Y; Iemura SI; van Dinther M; Natsume T; Ten Dijke P; Itoh S
    J Biol Chem; 2017 Mar; 292(10):4099-4112. PubMed ID: 28115518
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Transforming growth factor-β signalling controls human breast cancer metastasis in a zebrafish xenograft model.
    Drabsch Y; He S; Zhang L; Snaar-Jagalska BE; ten Dijke P
    Breast Cancer Res; 2013 Nov; 15(6):R106. PubMed ID: 24196484
    [TBL] [Abstract][Full Text] [Related]  

  • 43. SHIP represses lung inflammation and inhibits mammary tumor metastasis in BALB/c mice.
    Hamilton MJ; Halvorsen EC; LePard NE; Bosiljcic M; Ho VW; Lam V; Banáth J; Bennewith KL; Krystal G
    Oncotarget; 2016 Jan; 7(4):3677-91. PubMed ID: 26683227
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pyridoxine 5'-phosphate oxidase is a novel therapeutic target and regulated by the TGF-β signalling pathway in epithelial ovarian cancer.
    Zhang L; Zhou D; Guan W; Ren W; Sun W; Shi J; Lin Q; Zhang J; Qiao T; Ye Y; Wu Y; Zhang Y; Zuo X; Connor KL; Xu G
    Cell Death Dis; 2017 Dec; 8(12):3214. PubMed ID: 29238081
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function.
    Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H
    Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450
    [TBL] [Abstract][Full Text] [Related]  

  • 46. TGF-β inhibition enhances chemotherapy action against triple-negative breast cancer.
    Bhola NE; Balko JM; Dugger TC; Kuba MG; Sánchez V; Sanders M; Stanford J; Cook RS; Arteaga CL
    J Clin Invest; 2013 Mar; 123(3):1348-58. PubMed ID: 23391723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer.
    Marshall JC; Collins JW; Nakayama J; Horak CE; Liewehr DJ; Steinberg SM; Albaugh M; Vidal-Vanaclocha F; Palmieri D; Barbier M; Murone M; Steeg PS
    J Natl Cancer Inst; 2012 Sep; 104(17):1306-19. PubMed ID: 22911670
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
    Takai K; Le A; Weaver VM; Werb Z
    Oncotarget; 2016 Dec; 7(50):82889-82901. PubMed ID: 27756881
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
    Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
    Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
    Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
    Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Co-treatment with vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer.
    Choi J; Park J; Cho I; Sheen Y
    Radiol Oncol; 2022 Apr; 56(2):185-197. PubMed ID: 35390248
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
    Komuro A; Yashiro M; Iwata C; Morishita Y; Johansson E; Matsumoto Y; Watanabe A; Aburatani H; Miyoshi H; Kiyono K; Shirai YT; Suzuki HI; Hirakawa K; Kano MR; Miyazono K
    J Natl Cancer Inst; 2009 Apr; 101(8):592-604. PubMed ID: 19351925
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Transforming growth factor-beta1 protects against pulmonary artery endothelial cell apoptosis via ALK5.
    Lu Q
    Am J Physiol Lung Cell Mol Physiol; 2008 Jul; 295(1):L123-33. PubMed ID: 18456797
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Inhibition of breast cancer metastases by a novel inhibitor of TGFβ receptor 1.
    Fang Y; Chen Y; Yu L; Zheng C; Qi Y; Li Z; Yang Z; Zhang Y; Shi T; Luo J; Liu M
    J Natl Cancer Inst; 2013 Jan; 105(1):47-58. PubMed ID: 23178439
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Toxicodendron vernicifluum Stokes extract inhibits solid tumor growth and lung metastasis of 4T1 murine mammary carcinoma cells in BALB/c mice.
    Lee HS; Jung JI; Kim KH; Park SJ; Kim EJ
    PLoS One; 2020; 15(11):e0241805. PubMed ID: 33152052
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tranilast inhibits cell proliferation and migration and promotes apoptosis in murine breast cancer.
    Subramaniam V; Chakrabarti R; Prud'homme GJ; Jothy S
    Anticancer Drugs; 2010 Apr; 21(4):351-61. PubMed ID: 20145538
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Small molecular inhibitor of transforming growth factor-beta protects against development of radiation-induced lung injury.
    Anscher MS; Thrasher B; Zgonjanin L; Rabbani ZN; Corbley MJ; Fu K; Sun L; Lee WC; Ling LE; Vujaskovic Z
    Int J Radiat Oncol Biol Phys; 2008 Jul; 71(3):829-37. PubMed ID: 18411002
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Novel ALK5 inhibitor TP0427736 reduces TGF-β　induced growth inhibition in human outer root sheath cells and elongates anagen phase in mouse hair follicles.
    Naruse T; Aoki M; Fujimoto N; Arase S; Oura H; Ueda Y; Ikeda A
    Pharmacol Rep; 2017 Jun; 69(3):485-491. PubMed ID: 28324846
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Knockdown of the transforming growth factor-beta type III receptor impairs motility and invasion of metastatic cancer cells.
    Criswell TL; Dumont N; Barnett JV; Arteaga CL
    Cancer Res; 2008 Sep; 68(18):7304-12. PubMed ID: 18794117
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Transforming growth factor-beta signaling at the tumor-bone interface promotes mammary tumor growth and osteoclast activation.
    Futakuchi M; Nannuru KC; Varney ML; Sadanandam A; Nakao K; Asai K; Shirai T; Sato SY; Singh RK
    Cancer Sci; 2009 Jan; 100(1):71-81. PubMed ID: 19038005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.